
    
      Patients with locally advanced rectal cancer (cT3-4 or N+) are assigned to receive
      preoperative 5 Ã— 5 Gy irradiation over 5 days with consolidation chemotherapy consisting two
      cycles of CAPOX chemotherapy and camrelizumab, an anti-PD-1 antibody drug for two cycles.
      Subsequent surgical therapy is performed to evaluate the safety and efficacy.
    
  